Fierce Biotech22h
Opko, Entera share ownership of first oral GLP-1/glucagon agonist set to enter clinic
The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...
Healio21h
Societies take stand against off-brand GLP-1s over safety concerns
A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...
MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
Enrollment complete in Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism; topline results on track for Q3 2025MBX 1416 Phase 2 trial in ...
At Current Prices GLP-1s Aren’t Cost-Effective, Limiting Access To Patients
GLP-1s can deliver value to patients. But the fact that GLP-1s aren't cost-effective at their current net prices can limit ...